Advertisement

Archives of Gynecology and Obstetrics

, Volume 298, Issue 3, pp 477–485 | Cite as

Do probiotics effectively ameliorate glycemic control during gestational diabetes? A systematic review

  • Suelen Dallanora
  • Yasmin Medeiros de Souza
  • Rúbia Garcia Deon
  • Clare A. Tracey
  • Ana Amélia Freitas-Vilela
  • Luiz Fernando Wurdig Roesch
  • Roberta Hack Mendes
Review

Abstract

Background

Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition during pregnancy. The aim of this work was to systematically review all studies in which probiotic supplements were used during pregnancy and analyse the effects on GDM.

Methods

The data were collected using the medical subheading (MeSH) terms: (“diabetes, gestational”[MeSH Terms] OR (“diabetes”[All Fields] AND “gestational”[All Fields]) OR “gestational diabetes”[All Fields] OR (“gestational”[All Fields] AND “diabetes”[All Fields])) AND (“probiotics”[MeSH Terms] OR “probiotics”[All Fields]). The search included original articles written in English/Portuguese and published between 2012 and 2017.

Results

Of the 31 articles identified, seven met the inclusion criteria and were included in this review. In these studies, the sample size ranged from 60 to 373 women with GDM, which was between 24 and 40 weeks of pregnancy (second and third trimesters). Results demonstrated that probiotics used during pregnancy in women with GDM may improve glycaemic control and reduce VDL cholesterol, triglycerides, and inflammatory markers.

Conclusions

The present systematic review highlights the importance of probiotics for glycemic control and decrease of inflammatory markers in GDM. Further long-term studies should be conducted to elucidate this interaction.

Keywords

Gestational diabetes Gut microbiome Lactobacillus Bifidobacterium 

Notes

Author contributions

SD: Lead, the author worked on the conceptualization of the idea, search of the articles, data extraction and writing of original draft, review and editing. of manuscript. YM: the author worked on the search of articles, data extraction and support on the writing of original draft of manuscript. RGD: the author supported on the project administration and writing of original draft, review and editing of manuscript. CAT: the author supported on the writing of the original draft, review and editing. LR: the author supported on the conceptualization of the idea, writing of original draft, review and editing of the manuscript. AFV: the author supported on the project administration and writing of original draft, review and editing of the manuscript. RHM: the author worked on the conceptualization of the idea, project administration, methodology, writing of original draft, review and editing of the manuscript.

Compliance with ethical standards

Conflict of interest

No support  was received from any organization for the submitted work. S.D., Y.M., R.G.D., A.A.F.V., L.F.R. and R.H.M. declare that they have no conflict of interest.

References

  1. 1.
    Poomalar GK (2015) Changing trends in management of gestational diabetes mellitus. World J Diabetes [Internet] 6(2):284. http://www.wjgnet.com/1948-9358/full/v6/i2/284.htm
  2. 2.
    Milech A, Angelucci AP, Golbert A, Matheus A (2016) Diretrizes da Sociedade Brasileira de Diabetes (2015–2016). A.C. Farmacêutica. http://www.diabetes.org.br/profissionais/images/docs/DIRETRIZES-SBD-2015-2016.pdf
  3. 3.
    International Diabetes Federation (2015) IDF Diabetes Atlas. International Diabetes Federation. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.ht
  4. 4.
    Canadian Diabetes Association (2008) Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 32(suppl 1):S1–S201. http://www.diabetesclinic.ca/en/pdf/CDA_cpg-2008.pdf
  5. 5.
    Hirst JE, Raynes-Greenow CH, Jeffery HE (2012) A systematic review of trends of gestational diabetes mellitus in Asia. J Diabetol 3(3):4Google Scholar
  6. 6.
    Elessawy M, Harders C, Kleinwechter H, Demandt N, Sheasha GA, Maass N et al (2017) Measurement and evaluation of fetal fat layer in the prediction of fetal macrosomia in pregnancies complicated by gestational diabetes. Arch Gynecol Obstet 296:445–453CrossRefPubMedGoogle Scholar
  7. 7.
    Rasmussen AH, Wehberg S, Fenger-Groen J, Christesen HT (2017) Retrospective evaluation of a national guideline to prevent neonatal hypoglycemia. Pediatr Neonatol 5(5):398–405CrossRefGoogle Scholar
  8. 8.
    Agha-Jaffar R, Oliver N, Johnston D, Robinson S (2016) Gestational diabetes mellitus: does an effective prevention strategy exist? Nat Rev Endocrinol [Internet] 12(9):533–546. http://www.nature.com/doifinder/10.1038/nrendo.2016.88
  9. 9.
    Jafarnejad S, Saremi S, Jafarnejad F, Arab A (2016) Effects of a multispecies probiotic mixture on glycemic control and Inflammatory status in women with gestational diabetes: a randomized controlled clinical trial. J Nutr Metab 2016:5190846CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kuang YS et al (2017) Connections between the human gut microbiome and gestational diabetes mellitus. Gigascience 6(8):1–12CrossRefGoogle Scholar
  11. 11.
    Paixão LA, Castro FF dos S (2016) Colonização da microbiota intestinal e sua influência na saúde do hospedeiro. Univ Ciências da Saúde [Internet] 14(1):85–96. http://www.publicacoes.uniceub.br/index.php/cienciasaude/article/view/3629
  12. 12.
    Bäckhed F, Ding H, Wang T, Hooper L V, Koh GY, Nagy A, et al (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA [Internet] 101(44):15718–15723. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=524219&tool=pmcentrez&rendertype=abstract
  13. 13.
    Abbott A (2016) Scientists bust myth that our bodies have more bacteria than human cells. Nature.  https://doi.org/10.1038/natureza.2016.19136 Google Scholar
  14. 14.
    Sender R, Fuchs S, Milo R (2016) Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 14(8):e1002533CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    WHO (2002) Guidelines for the evaluation of probiotics in food. London, Ontario, Canada. http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf. Accessed 05 Sept 2017
  16. 16.
    Roesch LFW, Silveira RC, Corso AL, Dobbler PT, Mai V, Rojas BS et al (2017) Diversity and composition of vaginal microbiota of pregnant women at risk for transmitting group B Streptococcus treated with intrapartum penicillin. PLoS One 12(2):e169916CrossRefGoogle Scholar
  17. 17.
    FAO/WHO. Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada; 2002. [cited 2016 Dez 19]. http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf
  18. 18.
    Blaser M (2011) Antibiotic overuse: Stop the killing of beneficial bacteria. Nature [Internet] 476(7361):393–394. http://www.nature.com/doifinder/10.1038/476393a
  19. 19.
    Stavrou G, Kotzampassi K (2017) Gut microbiome, surgical complications and probiotics. Ann Gastroenterol 30(1):45–53PubMedGoogle Scholar
  20. 20.
    Gomez Arango LF, Barrett HL, Callaway LK, Nitert MD (2015) Probiotics and pregnancy. Curr Diabetes Rep 15:567CrossRefGoogle Scholar
  21. 21.
    Gohir W, Ratcliffe EM, Sloboda DM (2015) Of the bugs that shape us: maternal obesity, the gut microbiome, and long-term disease risk. Pediatr Res [Internet] 77(1–2):196–204. http://www.nature.com/doifinder/10.1038/pr.2014.169
  22. 22.
    Singh S, Karagas MR, Mueller NT (2017) Charting the maternal and infant microbiome: what is the role of diabetes and obesity in pregnancy? Curr Diabetes Rep 17:11CrossRefGoogle Scholar
  23. 23.
    Nogueira JCR (2011) Probióticos—Revisão da Literatura. Rev Bras Ciências da Saúde [Internet] 15(4):487–492. http://periodicos.ufpb.br/ojs2/index.php/rbcs/article/viewFile/8201/6858
  24. 24.
    Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. p. Table 7.7.a: formulae for combining groupsGoogle Scholar
  25. 25.
    The Prisma Group from Moher D, Liberati A, Tetzlaff JAD (2009) Preferred reporting items for systematic reviews and meta analyses: the Prisma statement. PLoS Med [Internet] 6(7):1000097. http://www.prisma-ststement.org
  26. 26.
    Asemi Z, Samimi M, Tabassi Z, Naghibi Rad M, Rahimi Foroushani A, Khorammian H et al (2013) Effect of daily consumption of probiotic yoghurt on insulin resistance in pregnant women: a randomized controlled trial. Eur J Clin Nutr [Internet] 67(1):71–74. http://www.nature.com/doifinder/10.1038/ejcn.2012.189
  27. 27.
    Lindsay KL, Kennelly M, Culliton M, Smith T, Maguire OC, Shanahan F et al (2014) Probiotics in obese pregnancy do not reduce maternal fasting glucose: a double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study). Am J Clin Nutr 99(6):1432–1439CrossRefPubMedGoogle Scholar
  28. 28.
    Dolatkhah N, Hajifaraji M, Abbasalizadeh F, Aghamohammadzadeh N, Mehrabi Y, Abbasi MM (2015) Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. J Health Popul Nutr 33(1):25CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lindsay KL, Brennan L, Kennelly MA, Maguire OC, Smith T, Curran S et al (2015) Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. Am J Obstet Gynecol 212(4):496.e1–496.e11CrossRefGoogle Scholar
  30. 30.
    Karamali M, Dadkhah F, Sadrkhanlou M, Jamilian M, Ahmadi S, Tajabadi-Ebrahimi M et al (2016) Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 42(4):234–241CrossRefPubMedGoogle Scholar
  31. 31.
    Wickens KL, Barthow CA, Murphy R, Abels PR, Maude RM, Stone PR et al (2017) Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Br J Nutr [Internet] 117(6):804–813. https://www.cambridge.org/core/product/identifier/S0007114517000289/type/journal_article
  32. 32.
    Hyronimus B, Le Marrec C, Urdaci MC (1998) Coagulin, a bacteriocin-like inhibitory substance produced by Bacillus coagulans I4. J Appl Microbiol 85(1):42–50CrossRefPubMedGoogle Scholar
  33. 33.
    Jamilian M, Bahmani F, Vahedpoor Z, Salmani A, Tajabadi-Ebrahimi M, Jafari P et al (2016) Effects of probiotic supplementation on metabolic status in pregnant women: a randomized, double-blind, placebo-controlled trial. Arch Iran Med 19(10):687–692PubMedGoogle Scholar
  34. 34.
    Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T et al (2010) Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis 16(8):1286–1298CrossRefPubMedGoogle Scholar
  35. 35.
    Homayouni Rad A, Torab R, Ghalibaf M, Norouzi S, Mehrabany EV (2013) Might patients with immune-related diseases benefit from probiotics? Nutrition. 29(3):583–586CrossRefPubMedGoogle Scholar
  36. 36.
    Yadav H, Lee JH, Lloyd J, Walter P, Rane SG (2013) Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 288(35):25088–25097CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Nakamura YK, Omaye ST (2012) Metabolic diseases and pro- and prebiotics: mechanistic insights. Nutr Metab (Lond) [Internet] 9(1):60. http://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-9-60
  38. 38.
    Oliveira AM, Hammes TO (2016) Microbiota e barreira intestinal: implicações para obesidade TT—microbiota and intestinal barrier: implications for obesity. Clin biomed res [Internet] 36:222–229. http://seer.ufrgs.br/index.php/hcpa/article/view/67683/pdf
  39. 39.
    McLachlan K a, O’Neal D, Jenkins A, Alford FP (2006) Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metab Res Rev [Internet] 22(2):131–138. http://www.ncbi.nlm.nih.gov/pubmed/16170833
  40. 40.
    Lu HL, Wang HW, Wen Y, Zhang MX, Lin HH (2006) Roles of adipocyte derived hormone adiponectin and resistin in insulin resistance of type 2 diabetes. World J Gastroenterol 12(11):1747–1751CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Gwozdziewiczová S, Lichnovská R, Hrebícek J (2004) Tumor necrosis factor alfa (TNFalpha) and insulin resistance. Ceskoslov Fysiol Ustred Ust Biol 53:167–175Google Scholar
  42. 42.
    Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier JC, Huston-Presley L, Friedman JE et al (2002) TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes 51:2207–2213CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Suelen Dallanora
    • 1
    • 2
  • Yasmin Medeiros de Souza
    • 1
  • Rúbia Garcia Deon
    • 1
  • Clare A. Tracey
    • 5
    • 6
  • Ana Amélia Freitas-Vilela
    • 3
  • Luiz Fernando Wurdig Roesch
    • 4
  • Roberta Hack Mendes
    • 1
    • 5
  1. 1.Universidade Regional Integrada do Alto Uruguai e das Missões-URIFrederico WestphalenBrazil
  2. 2.Instituto de Cardiologia do Rio Grande do SulPorto AlegreBrazil
  3. 3.Unidade Acadêmica Especial de Ciências da Saúde, Curso de Medicina, Universidade Federal de Goiás/Regional JataíJataíBrazil
  4. 4.Universidade Federal do PampaSão GabrielBrazil
  5. 5.University College Dublin, Science Centre SouthDublinIreland
  6. 6.Maastricht UniversityMaastrichtThe Netherlands

Personalised recommendations